MLTX
HEALTHCAREMoonLake Immunotherapeutics - Class A
Live · NASDAQ · May 9, Close
What's Moving MLTX Today?
No stock-specific AI insight has been generated for MLTX yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$17.70
Fundamentals
Trading
MLTX News
20 articles- Avalo shares spike on skin drug data; BioNTech to cut staffBiopharmadive·May 6, 2026
- The CEO of MoonLake Immunotherapeutics Dumped Shares Worth $2.8 Million. Should Investors Avoid the Stock?The Motley Fool·Apr 18, 2026
- Biotech Fund BVF Trims MoonLake Stake, Sells $63M in SharesThe Motley Fool·Apr 7, 2026
- How Investors Are Reacting To MoonLake Immunotherapeutics (MLTX) Long-Term Sonelokimab Data In Hidradenitis SuppurativaYahoo Finance·Apr 5, 2026
- MoonLake’s lead asset shows durability in late-stage HS studiesClinicaltrialsarena·Mar 31, 2026
- MoonLake Trial Data Continue to Support Efficacy of Sonelokimab to Treat Hidradenitis Suppurativa, Wedbush SaysYahoo Finance·Mar 30, 2026
- MoonLake announces Week 40 Results from its Phase 3 Clinical Trials of Sonelokimab in Hidradenitis Suppurativa at the 2026 AAD Annual MeetingGlobeNewswire Inc.·Mar 28, 2026
- Micron downgraded, Five Below upgraded: Wall Street's top analyst callsYahoo Finance·Mar 19, 2026
- This Fund Bought $28 Million of a Beaten-Down Immunotherapy Stock Last Quarter. What Should Long-Term Investors Know?Motley Fool·Mar 16, 2026
- Goldman Questions MoonLake Immunotherapeutics’ (MLTX) Sonelokimab Approval Odds Despite Pipeline UpdateYahoo Finance·Mar 2, 2026
- Assessing MoonLake Immunotherapeutics (MLTX) Valuation After Mixed Share Price Performance And Premium P/B RatioYahoo Finance·Mar 1, 2026
- MoonLake Immunotherapeutics (MLTX) Is Down 6.7% After Mixed 2025 Results And AxSpA Data Update - What's ChangedYahoo Finance·Feb 28, 2026
- Structure Therapeutics Stock Soars Over 200% as One Fund Adds to a $242 Million PositionMotley Fool·Feb 25, 2026
- Protagonist Stock Up 120%, but One Fund Just Revealed a $170 Million ExitMotley Fool·Feb 25, 2026
- Disc Medicine Stock Is Swinging, but This Fund's New $52 Million Bet Shows ConvictionMotley Fool·Feb 25, 2026
- MoonLake Immunotherapeutics Investor Day: HS BLA on Track, axSpA Phase 2 Data Highlights Imaging WinsMarketbeat·Feb 24, 2026
- MoonLake Announces Positive Topline Results from its Phase 2 Clinical Trial of Sonelokimab in Axial Spondyloarthritis and Reports 2025 Financial ResultsYahoo Finance·Feb 22, 2026
- MoonLake Immunotherapeutics (MLTX) Valuation Check After Mixed Share Price PerformanceYahoo Finance·Feb 13, 2026
- ImageneBio Appoints Immunology Drug Development Veteran Dr. Ben Porter-Brown as Chief Medical OfficerYahoo Finance·Feb 10, 2026
- Goldman Sachs Notes VELA-2 Failure, Calls MoonLake Immunotherapeutics (MLTX) a High-Risk PlayYahoo Finance·Feb 2, 2026
All 20 articles loaded
Price Data
52-Week Range
$17.70
Fundamentals
Trading
About MoonLake Immunotherapeutics - Class A
MoonLake Immunotherapeutics is an innovative biotechnology firm dedicated to developing groundbreaking therapies for chronic inflammatory diseases, leveraging its proprietary drug delivery technology. Currently, the company is advancing its lead candidate, a novel interleukin-17 inhibitor, through various stages of clinical trials, with the potential to transform treatment paradigms and improve patient outcomes significantly. Backed by a robust research pipeline and strategic collaborations, MoonLake is strategically positioned within the immunotherapy sector, targeting significant unmet medical needs while creating potential value for investors.